Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

This item appears in the following Collection(s)

Available in accordance with the Publisher Policy. Please refer to the publisher's site for terms of use.

Search Repository


My Account

Statistics